HORIZON LINES: A QUARTERLY REVIEW OF NDAs
HORIZON LINES A Quarterly Review of NDAs - 2Q14
Harshada Sant, MS and Hemant N. Joshi, PhD, MBA*
Tara Innovations LLC, *
hemantjoshi@tarainnovations.com
Sant H, Joshi H. Horizon lines: a quarterly review of NDAs. Pharm Outsourcing. 2015;16(2),58-61.
This column summarizes New Drug Applications (NDAs) for the third quarter 2014 (July through September 2014). In this quarter, FDA approved 38 NDAs.
Thirty (78.9%) NDAs were for small molecules while the remaining 8 molecules (21.1%) were large molecules. Similar to the previous quarter, there is a continued interest in working on the large molecules. In this quarter, 18 companies (47.4%) receiving NDA approvals were large companies and the remaining 20 companies (52.6%) were mid-sized and small companies. Ten drug molecules were granted the Orphan Drug Status (26.3%). Boehringer Ingelheim and Gilead Sciences bagged 3 NDAs each in this quarter. Tablets and injections were the preferred dosage forms. Four out of 38 (10.5%) NDAs were combination dosage forms, out of which Triumeq (indicated for HIV infection) had 3 different drugs.
FDA approved Ozurdex (dexamethasone) 0.7 mg, a sustained-release biodegradable steroid implant for the treatment of general diabetic macular edema (DME) patients. Ozurdex was originally approved in June 2014 as a treatment for DME in adult patients who have an artificial lens implant or who are scheduled for cataract surgery. Similarly, Minivelle (estradiol transdermal system) was initially approved by the FDA in October 2012 to treat moderate to severe vasomotor symptoms due to menopause. FDA approved a new indication with a new dose of Minivelle for the prevention of postmenopausal osteoporosis.
Tablets can be split correctly with the help of score marks. Acticlate tablets (150 mg) have been scored twice so that patients can take 3 doses of 50-mg doxycycline hyclate from a single tablet.
FDA has
approved Targiniq ER, a new extended-release pain reliever that contains a combination of oxycodone and naloxone. Targiniq ER is the second extended-release/long-acting opioid analgesic with FDA- approved labeling describing the product’s properties that are expected to reduce, but not totally prevent, abuse by snorting or injecting. FDA suggested Drug Safety Labeling Changes for Lumizyme which include a boxed warning, precautions, and adverse reactions.
Nine out of 12 (75%) novel new drugs (NNDs) were approved in the US before any other countries.
Eight out of the 38 (21.05%) NDAs received approval for a new formulation or a new indication or an altered patient population or a new dosage form for the same drug, etc. These molecules had received NDAs previously. New indications were approved for Imbruvica, Eylea,
Pharmaceutical Outsourcing | 58 | March/April 2015
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78